NCT04210713 is a Phase 1 clinical trial of Minocycline in Alcohol Drinking, sponsored by University of Maryland, Baltimore.

Who is sponsoring NCT04210713?

NCT04210713 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT04210713?

Interventions in NCT04210713: Minocycline, Sugar pill.

What condition does NCT04210713 study?

NCT04210713 studies Alcohol Drinking, Alcohol-Related Disorders, Disease, Inflammation, Alcoholism, Cognitive Dysfunction, Pathologic Processes, Drinking Behavior, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Cognition Disorder, Neurocognitive Disorders, Minocycline, Anti-Bacterial Agents, Anti-Infective Agents.

Is NCT04210713 still recruiting?

NCT04210713 is currently completed. Last updated 1 December 2023.

Last reviewed 2023-12-01 · How we verify

NCT04210713

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroimmune Dysfunction in Alcohol Use Disorder

Completed Phase 1 Last updated 1 December 2023

What this trial tests

Phase 1 trial testing Minocycline in Alcohol Drinking in 142 participants. Completed in 20 September 2023.

Timeline

3 February 2020

Primary endpoint
20 September 2023

20 September 2023

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	142
Start date	3 February 2020
Primary completion	20 September 2023
Estimated completion	20 September 2023
Sites	1 location across United States

Drugs / interventions tested

Minocycline (MINOCYCLINE) — full drug profile →
Sugar pill

Conditions studied

Alcohol Drinking — all drugs for Alcohol Drinking →
Alcohol-Related Disorders — all drugs for Alcohol-Related Disorders →
Disease — all drugs for Disease →
Inflammation — all drugs for Inflammation →

Sponsor

University of Maryland, Baltimore

Who can join

Adults 25 to 65, any sex, with Alcohol Drinking or Alcohol-Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immune treatments for alcohol use disorder: A translational framework.
Meredith LR, Burnette EM, Grodin EN, Irwin MR, et al · · 2021 · cited 50× · PMID 34343618 · DOI 10.1016/j.bbi.2021.07.023
Alcohol Use Disorder and the Gut-Brain Axis: A Narrative Review of the Role of Gut Microbiota and Implications for Treatment.
Shukla S, Hsu CL. · · 2025 · cited 9× · PMID 39858835 · DOI 10.3390/microorganisms13010067
Promising immunomodulators for management of substance and alcohol use disorders.
Acuña AM, Park C, Leyrer-Jackson JM, Olive MF. · · 2024 · cited 5× · PMID 38803314 · DOI 10.1080/14656566.2024.2360653
Therapeutic targeting of neuroinflammation in methamphetamine use disorder.
Jeffery N, Mock PY, Yang K, Tham CL, et al · · 2025 · cited 3× · PMID 39727147 · DOI 10.1080/17568919.2024.2447226
Central amygdala neuroimmune signaling in alcohol use disorder.
Melkumyan M, Randall PA, Silberman Y. · · 2025 · cited 2× · PMID 40336623 · DOI 10.1016/j.addicn.2024.100194
ACNP 62nd Annual Meeting: Poster Abstracts P501 – P753
· 2023 · cited 1×
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.
McManus KR, Ray LA. · · 2026 · PMID 41611606 · DOI 10.1080/17512433.2026.2625341
ACNP 63rd Annual Meeting: Poster Abstracts P1-P304
· 2024

Verify or expand the search:

Other trials of Minocycline

Trials testing the same drug.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07305896 — Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage · NA · not yet recruiting
NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio · Phase 4 · recruiting
NCT06523764 — Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment · Phase 4 · active not recruiting
NCT06120140 — Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small · Phase 2 · recruiting

Other recruiting trials for Alcohol Drinking

Currently open trials in the same condition.

NCT07415707 — The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in N · NA · recruiting
NCT06815237 — Effects of Ketone Supplement and Alcohol on Brain Metabolism · Phase 2, PHASE3 · recruiting
NCT06994962 — Multi-Component Breath Alcohol Intervention Phase 3 · NA · recruiting
NCT05363878 — Development of a Culturally Grounded, Trauma-Informed Alcohol Intervention With a Reserve-Dwelling First Nation Group · NA · recruiting
NCT06309134 — The Healthy Families Bright Futures Program · NA · recruiting

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04210713 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 1 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04210713.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing